Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Editorial infographic showing Johnson & Johnson’s Polyphonic surgical AI deployment in Abu Dhabi, featuring an AI-assisted operating room, robotic surgical technology, digital medical displays, and highlights on clinical validation, data governance and hospital adoption.
Medical Devices & Diagnostics

Johnson & Johnson advances surgical AI network with Abu Dhabi and Polyphonic platform

Johnson & Johnson advances Polyphonic surgical AI deployment in Abu Dhabi. Clinical validation, data governance and hospital adoption will shape its impact.

Read More
Representative image of invasive aspergillosis research as F2G and Shionogi report positive Phase 3 olorofim results, highlighting its potential as a new oral antifungal treatment.
Pharma & Biotech

Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis

F2G and Shionogi's oral olorofim meets Phase 3 aspergillosis endpoint with fewer kidney adverse events. Explore the results and FDA plans.

Read More
Representative image of uveitis research as Roivant Sciences and Priovant Therapeutics report positive Phase 3 brepocitinib results, reducing treatment failure and improving steroid-free disease control.
Pharma & Biotech

Roivant and Priovant report 62% steroid-free disease control with brepocitinib in uveitis trials

Roivant's brepocitinib succeeds in two Phase 3 uveitis trials, improving steroid-free disease control. Explore the results and FDA plans.

Read More
Representative image of ulcerative colitis research as Odyssey Therapeutics’ oral drug OD-001 achieves 27% clinical remission in a Phase 2a trial, showing promising treatment potential.
Pharma & Biotech

OD-001 ulcerative colitis study shows clinical response in 61% of higher-dose patients

Odyssey Therapeutics reports 27% remission with OD-001 in Phase 2a ulcerative colitis testing. Explore the findings and next clinical trials.

Read More
Representative image of Parkinson’s disease research as BioVie’s bezisterim shows promising Phase 2 improvements in motor and non-motor symptoms among patients with elevated inflammation.
Pharma & Biotech

Bezisterim Phase 2 results highlight potential new treatment approach for Parkinson’s disease symptoms

BioVie's bezisterim shows promising Phase 2 Parkinson's results in patients with elevated inflammation. Explore the findings and Phase 3 outlook.

Read More
Representative image of bipolar disorder clinical research as Rapport Therapeutics’ RAP-219 meets key Phase 2 trial endpoints, showing promising results in bipolar mania treatment.
Pharma & Biotech

Rapport Therapeutics’ RAP-219 delivers statistically significant bipolar mania improvements in Phase 2 trial

Rapport Therapeutics' RAP-219 meets Phase 2 bipolar mania endpoints. Explore its clinical results, safety findings and planned Phase 3 trials.

Read More
Editorial infographic showing TriGemX Bio’s planned $246 million SPAC transaction to support Phase 3 elismetrep trials, featuring laboratory imagery, clinical trial documents, financial charts, and key development milestones.
Pharma & Biotech

TriGemX Bio agrees $246m SPAC deal to advance elismetrep migraine trials

TriGemX Bio plans a $246 million SPAC transaction to fund Phase 3 elismetrep trials. Clinical results and deal completion will determine its future.

Read More
Editorial infographic showing Veradermics’ Phase 3 VDPHL01 hair growth study in 536 men, with hair follicle imagery, a clinical trial document, and references to efficacy, safety, and FDA review.
Pharma & Biotech

What the Veradermics Phase 3 results mean for oral minoxidil treatment

Veradermics reports strong Phase 3 VDPHL01 hair growth results in 536 men. Efficacy is encouraging, but safety and FDA review remain crucial.

Read More
Editorial infographic illustrating Summit Therapeutics’ global Phase 2 kidney cancer trial, featuring anatomical kidney imagery, a clinical trial document, a world map, and highlights of ivonescimab combination therapies compared with established immunotherapy.
Pharma & Biotech

Summit Therapeutics expands ivonescimab development with SMT112-216 trial

Summit Therapeutics opens a global Phase 2 kidney cancer trial testing ivonescimab combinations against established immunotherapy. What comes next?

Read More
Editorial infographic showing United Therapeutics’ FDA clearance for the SUMMIT PH-COPD trial, featuring a treprostinil inhaler, illustrated lungs, clinical trial imagery, and key safety considerations.
Pharma & Biotech

United Therapeutics advances SUMMIT study targeting pulmonary hypertension in COPD

United Therapeutics secures FDA clearance for its SUMMIT PH-COPD trial. Can a new treprostinil inhaler overcome earlier safety concerns?

Read More